EULAR干燥综合征局部与全身治疗管理建议
欧洲抗风湿病联盟(EULAR)依据2014年标准操作流程,组织30国多学科工作组制定首部干燥综合征(SjS)局部与全身用药的循证共识建议。建议含3条总体原则和12条具体推荐,按 dryness、疲劳、疼痛核心症状及系统性疾病顺序排列,并附证据等级与工作组同意度。
要点
- 治疗目标以缓解症状为主,无特定治疗靶点。
- 推荐按 dryness、疲劳、疼痛核心三联征后系统病变顺序管理。
- 涵盖局部口腔/眼部用药、毒蕈碱激动剂、HCQ、激素、免疫抑制剂及生物制剂。
核心结论
- EULAR发布首部干燥综合征局部与全身治疗循证共识建议,含3条总体原则和12条具体推荐。
研究设计与样本
- EULAR支持的国际协作研究(EULAR SS Task Force),按2014年EULAR标准操作流程制定。
- 工作组含风湿、内科、口腔、眼科、妇科、皮肤、流行病学、统计、全科、护理及患者代表,来自5大洲30国。
- 证据来自符合2002/2016分类标准的原发性SjS患者研究;无证据时考虑相关SjS或既往标准患者证据并外推。
主要发现
- 推荐按逻辑顺序从核心三联征(干燥、疲劳、疼痛)管理开始,随后管理系统性疾病。
- 推荐涉及局部口腔(唾液替代品)和眼部(人工泪液、局部NSAIDs、局部糖皮质激素、局部CyA、血清泪液)治疗。
- 推荐涉及口服毒蕈碱激动剂(毛果芸香碱、西维美林)、羟氯喹、口服糖皮质激素、合成免疫抑制剂及生物制剂。
- 每条推荐提供证据等级(多为中等)和工作组同意度(多为非常高)。
关键数值与推荐
- 总体原则为3条共识性推荐,具体推荐为12条。
- 证据等级多为中等(modest),工作组同意度多为非常高(very high)。
- 合成免疫抑制剂包括环磷酰胺、硫唑嘌呤、甲氨蝶呤、来氟米特和霉酚酸酯。
- 生物制剂包括利妥昔单抗、阿巴西普和贝利木单抗。
临床怎么用
- 临床可按核心症状(干燥、疲劳、疼痛)再到系统性疾病顺序选择局部或全身治疗。
- 局部口腔可用唾液替代品,眼部可用人工泪液、局部NSAIDs、局部糖皮质激素、局部CyA或血清泪液。
- 全身治疗可选口服毒蕈碱激动剂、羟氯喹、口服糖皮质激素、合成免疫抑制剂或生物制剂。
局限性
- 多数推荐证据等级为中等,证据强度有限。
- 无证据时采用相关SjS或既往分类标准患者证据外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain challenging in clinical practice, without a specific therapeutic target beyond the relief of symptoms as the most important goal. In view of this scenario, the European League Against Rheumatism (EULAR) promoted and supported an international collaborative study (EULAR SS Task Force) aimed at developing the first EULAR evidence and consensus-based recommendations for the management of patients with SjS with topical and systemic medications. The aim was to develop a rational therapeutic approach to SjS patients useful for healthcare professionals, physicians undergoing specialist training, medical students, the pharmaceutical industry and drug regulatory organisations following the 2014 EULAR standardised operating procedures. The Task Force (TF) included specialists in rheumatology, internal medicine, oral health, ophthalmology, gynaecology, dermatology and epidemiology, statisticians, general practitioners, nurses and patient representatives from 30 countries of the 5 continents. Evidence was collected from studies including primary SjS patients fulfilling the 2002/2016 criteria; when no evidence was available, evidence from studies including associated SjS or patients fulfilling previous sets of criteria was considered and extrapolated. The TF endorsed the presentation of general principles for the management of patients with SjS as three overarching, general consensus-based recommendations and 12 specific recommendations that form a logical sequence, starting with the management of the central triplet of symptoms (dryness, fatigue and pain) followed by the management of systemic disease. The recommendations address the use of topical oral (saliva substitutes) and ocular (artificial tear drops, topical non-steroidal anti-inflammatory drugs, topical corticosteroids, topical CyA, serum tear drops) therapies, oral muscarinic agonists (pilocarpine, cevimeline), hydroxychloroquine, oral glucocorticoids, synthetic immunosuppressive agents (cyclophosphamide, azathioprine, methotrexate, leflunomide and mycophenolate), and biological therapies (rituximab, abatacept and belimumab). For each recommendation, levels of evidence (mostly modest) and TF agreement (mostly very high) are provided. The 2019 EULAR recommendations are based on the evidence collected in the last 16 years in the management of primary 2002 SjS patients and on discussions between a large and broadly international TF. The recommendations synthesise current thinking on SjS treatment in a set of overarching principles and recommendations. We hope that the current recommendations will be broadly applied in clinical practice and/or serve as a template for national societies to develop local recommendations.
引用
- Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Ann Rheum Dis. 2019. PMID: 31672775. doi:10.1136/annrheumdis-2019-216114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。